Studies using early inhibitors such as UCN-01 and NU6027 provided much proof of principle and mechanistic evidence for the use of small molecule inhibitors of CHK1 and ATR, respectively in an anti-cancer setting [35,72]. This evidence concerns the gene ATR and cancer.